| Jun 18 |
FibroGen to Host Part II of Virtual KOL Investor Event Series to Review FG-3246 Development Program in Metastatic Castration-Resistant Prostate Cancer on June 26, 2024
|
| Jun 6 |
FibroGen: Two New In-Licensed Oncology Drugs To Carry It Forward
|
| Jun 4 |
Why HealthEquity Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
|
| Jun 3 |
FibroGen stock rallies 30% after hours on FG-3165, FG-3175 updates
|
| Jun 3 |
FibroGen Stock Is Surging After The Bell: What's Going On?
|
| Jun 3 |
FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen’s Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials
|
| Jun 3 |
FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors
|
| Jun 3 |
FibroGen to Present at Goldman Sachs 45th Annual Global Healthcare Conference
|
| May 28 |
7 Penny Biotech Stocks to Triple Your Investment
|
| May 28 |
Pamrevlumab And Roxadustat: Evaluating FibroGen's Future Amid Financial Strains
|
